GENE ONLINE|News &
Opinion
Blog

2022-07-05| ChinaManufacturing

WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou

by Joy Lin
Share To

WuXi Biologics is expanding its CDMO services to include microbial fermentation in its MFG14 facility in Hangzhou, the capital of China’s Zhejiang province. The plant has been performing CMC (chemistry, manufacturing and controls) services for clients since early 2022, said the company. 

Plans for introducing a microbial CDMO platform have been underway since 2019. In November, WuXi launched the Biologics Integrated Innovation Center in Hangzhou for end-to-end services for microbial-derived biologics. 

 

Microbial Fermentation and Processes

 

Many therapeutic products, ranging from anticancer drugs and vaccines to hormonal therapies such as insulin can be produced via microbial fermentation. The process uses microorganisms such as E. coli and yeast, and is fast, cost-effective and easy to scale-up. According to WuXi, the Hangzhou plant can produce enzymes, antibody fragments, recombinant proteins, virus-like particles, and plasmid DNA. 

WuXi’s platform provides the full course of CMC services, from strain development, process and analytical development, to cGMP manufacturing and QC release. Production is enabled by four cGMP manufacturing lines equipped with 30L to 2,000L fermentors, and is complemented by downstream processing capacities, drug substance formulation and filling capabilities. 

Related article: FDA Halts Sanofi’s $3.7B Multiple Sclerosis Investment

 

A Global CDMO With Ever-Growing Appetite 

 

WuXi Biologics has a presence in many countries including China, the US, Ireland, Singapore. More recently, the company expanded into Germany by acquiring two drug plants owned by Bayer. 

Besides the microbial-focused facility, the company has another biosimilar manufacturing plant in Hangzhou it acquired from Pfizer in 2021, after the drug giant decided to exit the Chinese biosimilar market despite major investments in the area. 

Elsewhere in China, WuXi Biologics acquired a biologics manufacturing site in Suzhou from CMAB, and maintains operational sites in Shanghai, Wuxi and Suzhou. Meanwhile, sites in Shijiazhuang and Chengdu are expected to begin operations in 2022 and 2023 respectively.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Moderna To Collaborate With Harbour BioMed On Nucleic Acid-Based Cancer Therapies
2022-11-14
WuXi Biologics, Toregem BioPharma To Develop Tooth-Regenerating Antibody
2022-10-14
Will Biden’s Biomanufacturing Initiative Kill Korean Partnership?
2022-10-12
LATEST
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
RemeGen Presented New Data Updates on Telitacicept for SLE and primary Sjogren’s syndrome at ACR Convergence 2022
2022-12-05
EMA Urges Pholcodine’s Removal from European Market Following Safety Study
2022-12-05
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
2022-12-04
Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion
2022-12-02
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
2022-12-02
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!